Immunohistochemistry is recommended after the pathology comes out, and there is not necessarily a correlation between the two, which is not necessarily serious. Immunohistochemistry is based on the principle of immunology, using the antigen-antibody reaction, so that the antibody binds to the antigen in the corresponding tissue cells, and carries out the localization, qualitative and quantitative examination of the antigen, which is widely used in the diagnosis and treatment of tumors. Immunohistochemistry is recommended after the pathology comes out, which is generally not necessarily related to its severity. Immunohistochemistry is used to further identify and characterize cancer, and to determine the source and type of cancer cells, in order to determine the next step in the treatment plan. Immunohistochemistry tests are able to examine the origin and degree of differentiation of cancer cells, and provide a basis for selecting the appropriate treatment plan according to their origin and degree of differentiation. Immunohistochemistry can also assist in the detection of small metastatic foci of cancer in the bone marrow and lymphocytes to determine the proliferative activity of the tumor tissue. Immunohistochemistry is also one of the indicators for evaluating the patient’s prognosis after cancer screening. The recommendation for immunohistochemistry after the pathology comes out does not necessarily correlate with its severity, so patients are advised to cooperate with their doctors to actively start treatment and examination for the best prognosis.